Genetron (NASDAQ:GTH) & Exact Sciences (NASDAQ:EXAS) Direct Analytics

0

Exact Sciences (NASDAQ: EXASGet a rating) and Genetron (NASDAQ: GTHGet a rating) are two medical companies, but which is the best investment? We’ll compare the two companies based on earnings strength, risk, profitability, dividends, analyst recommendations, valuation, and institutional ownership.

Profitability

This table compares the net margins, return on equity and return on assets of Exact Sciences and Genetron.

Net margins Return on equity return on assets
Exact Sciences -40.26% -21.82% -11.23%
Genetron -101.62% -41.44% -34.31%

Benefits and evaluation

This table compares the gross revenue, earnings per share and valuation of Exact Sciences and Genetron.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Exact Sciences $1.77 billion 4.73 -$595.63 million ($4.32) -11.01
Genetron $83.47 million 1.64 -77.87 million dollars ($0.95) -1.59

Genetron has lower revenues, but higher profits than Exact Sciences. Exact Sciences trades at a lower price-to-earnings ratio than Genetron, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent valuations and price targets for Exact Sciences and Genetron, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Exact Sciences 0 3 9 0 2.75
Genetron 0 0 1 0 3.00

Exact Sciences currently has a consensus target price of $101.33, indicating a potential upside of 113.11%. Genetron has a consensus target price of $10.00, indicating a potential upside of 562.25%. Given Genetron’s higher consensus rating and higher possible upside, analysts clearly believe that Genetron is more favorable than Exact Sciences.

Risk and Volatility

Exact Sciences has a beta of 1.24, which means its stock price is 24% more volatile than the S&P 500. In comparison, Genetron has a beta of 1.25, which means its stock price is 25% more volatile than the S&P 500.

Institutional and insider ownership

94.5% of Exact Sciences shares are held by institutional investors. By comparison, 20.1% of Genetron’s shares are held by institutional investors. 1.4% of Exact Sciences stock is held by company insiders. Strong institutional ownership indicates that endowments, large fund managers, and hedge funds believe a stock is poised for long-term growth.

Summary

Exact Sciences beats Genetron on 8 of the 14 factors compared between the two stocks.

About the exact sciences (Get a rating)

Exact Sciences Corporation provides cancer screening and diagnostic tests in the United States and around the world. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression test for breast, prostate and colon cancer; Oncotype Test, a tissue test providing tumor profiling to aid in treatment selection for patients with advanced, metastatic, refractory or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced prostate cancer; Oncomap ExTra, which provides a complete biological picture of certain refractory, rare or aggressive cancers; and Covid-19 testing services. The Company’s pipeline products focus on improving the performance characteristics of the Cologuard test and developing blood tests and other fluid-based tests. It has licensing agreements with the MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is based in Madison, Wisconsin.

About Genetron (Get a rating)

Genetron Holdings Limited, a precision oncology company, engages in the molecular profiling of cancer and harnesses molecular biology and data science technologies for the treatment of cancer. The company offers diagnostic and monitoring services, as well as early detection services through laboratory-developed testing services. It also provides in vitro diagnostic products, including 8-gene lung cancer test, IVD test product to detect lung cancer; Genetron 3D Microarray Reading Instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide by detecting the change in pH; Chef Genetron system; Genetron S2000 platform, a production scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. Additionally, it offers IDH1 and TERT gene testing for glioma; basic thyroid assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for cancer GIST; and HCCscan, a qPCR-based test to detect hepatocellular carcinoma. In addition, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies around the world. The company has a strategic partnership with JD Health to create solutions for the management of the complete cancer cycle. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, People’s Republic of China.



Get news and reviews for Exact Sciences Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Exact Sciences and related companies with MarketBeat.com’s free daily email newsletter.

Share.

Comments are closed.